CD 25 — AR226-3749-3768

EPA administrative record segment: CD-25--AR226-3749-3768 (24 documents).

Page 1 of 1 — 24 documents
Title / Summary Year AR226 Docket Hash ID Pages
This is a letter from Taft, Stettinius & Hollister LLP dated February 2, 2007, providing additional perfluorochemical exposure data for Washington County, Minnesota, to various EPA and Minnesota Department of Health officials for inclusion in the EPA's Administrative Record 226. 2007 AR226-3749 zdGq2nLbDE7nwaL3nBL5yjDGa 12
The Minnesota Department of Health announced the detection of low levels of perfluorobutanoic acid (PFBA) in municipal wells across six cities, indicating no immediate health risk but prompting an investigation into the contamination source. 2007 AR226-3750 J3Dmm05aY9jRmb5bpXwZ1ny66 9
The document is a correspondence from DuPont Chemical Solutions Enterprise, dated March 7, 2007, providing additional information on studies related to the global fate and exposure potential of DuPont's fluorotelomer products and their biodegradation, following a meeting with the EPA. 2007 AR226-3753 bO489OJgyE46Db5RmLVoZqjLg 28
This document is a letter from DuPont's legal counsel to the EPA regarding the submission of sanitized versions of documents related to PFOA for the AR-226 public file, clarifying that the transmittal letter does not contain confidential business information. 2007 AR226-3754 vykXnDRKqk110q602vxzNRqaY 2
3M submitted a corrected copy of a study report on the effects of perfluorinated alkyl sulfonates, specifically focusing on cholesterol and bile acid metabolism in transgenic mice and fatty acid conversion in rat hepatocytes, to the EPA's AR-226 docket. 2007 AR226-3757 DGa0jjZeaLmRX0RmvjvqNaxK5 4
The document is a March 7, 2007 letter from DuPont to the EPA providing additional information on a peer-reviewed study regarding the global fate and exposure potential of DuPont's Fluorotelomer products, as well as details on biodegradation studies conducted by DuPont. 2007 AR226-3756 o9j1nDKO2LKVLXVVoKpag6o1r 51
The document is a March 7, 2007 letter from DuPont to the EPA providing additional information on a comprehensive, peer-reviewed study commissioned by DuPont and conducted by Environ regarding the global fate and exposure of fluorotelomer-based compounds. 2007 AR226-3755 a1X1xL8w5LGLNwMknVXr9Qnkb 79
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding preliminary data indicating that perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) may affect body weight, food consumption, and serum cholesterol in transgenic mice. 2007 AR226-3763 4QVYELa72YxkxxNZbLd5NR8ze 1
3M notified the EPA of preliminary findings from a study indicating that perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) may affect body weight, food consumption, and serum cholesterol in E3 Leiden transgenic mice. 2007 AR226-3764 YDRQk4eEMGqRB9mmJezQ03qny 1
3M submitted a TSCA 8(e) substantial risk notice to the EPA, reporting preliminary findings from a study indicating that perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) may affect body weight, food consumption, and serum cholesterol in transgenic mice. 2007 AR226-3765 nnVBYQ4qYZ9wkmvrXrvnZmJ2 1
3M submitted a TSCA 8(e) Substantial Risk Notice detailing the detection of Perfluorooctanoic Acid (PFOA), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in groundwater samples from residential wells near its Decatur, Alabama facility, with PFOA levels averaging 0. 2007 AR226-3766 Qgx0q5dwEjG1evaoO8VEbxO7k 1
This document is a letter from DuPont Haskell Laboratory to the EPA, providing a supplement to an ongoing study on perfluorooctanoate (PFOA) that examines health status and serum biomarker exposure among employees at the DuPont Washington Works plant, reporting that while serum PFOA levels were positively associated with certain health parameters, the clinical significance of these associations is unlikely. 2007 AR226-3767 ZJYEgXQJa75QzJ3R5yBLnnpjJ 2
This letter from DuPont provides a supplement to a previous submission regarding a longitudinal study on perfluorooctanoate (PFOA), indicating that increased serum PFOA levels are associated with higher total cholesterol and changes in liver function indicators among employees at the DuPont Washington Works plant, although DuPont does not consider this information to constitute substantial risk under TSCA 8(e). 2007 AR226-3768 mq9x01doDon6DaLkRqo7vZO6B 2
This interim report details the analysis of Perfluorooctanoic Acid (PFOA) in various environmental samples for the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards. 2007 AR226-3766 okRQL1bbVDQVpQyqzBDDb8n3 119
Interim Report #26 details the analysis of Perfluorobutanesulfonate (PFBS), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in various environmental samples as part of the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards 2007 AR226-3766 6Rdde8QqOyqOKkjbQNvekgz23 118
This document presents the results of an analysis of aqueous samples for various perfluorinated compounds, including PFOA and PFOS, conducted by AXYS Analytical Services Ltd., revealing specific concentration levels and recovery percentages for each compound. 2006 AR226-3751 DMnZL7QeymGZM9nnRd7qew3vO 2
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, providing supplemental analytical reports on Perfluorobutanesulfonate (PFBS), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) from its ongoing monitoring program at the Decatur, Alabama facility. 2006 AR226-3762 85OV4bBdnpgJzezjM2pKD1jq5 2
This dissertation by Benjamin Joseph Apelberg investigates fetal exposure to perfluorinated compounds (PFCs), focusing on their distribution, determinants of exposure, and relationships with weight and size at birth. 2006 AR226-3759 OzG5rMVErRBMv7DnKaGNrGmLX 222
This is an appendix to the TNO report of study 3M-02, detailing various measurements and analyses conducted on E3L mice, prepared for 3M's Medical Department. 2006 AR226-3763 zQk4wpM6de1dKOQ0dx5jqbYan 172
This document is an analytical report from AXYS Analytical Services detailing the detection of various perfluorinated compounds, including PFOS, in serum samples collected on March 8, 2005, with specific concentration values and laboratory flags indicating detection limits. 2005 AR226-3752 85EnkDM31zOaG71470GNaG1oK 15
The document discusses blood test results for C-8 (PFOA) in pensioners from DuPont, indicating a half-life estimate of about four years based on comparisons of blood levels from 1995 and 2000 after retirement. 2000 AR226-3761 X7V3Jyn2Vx1Ro9zmZnaoZ3bp4 1
The TNO report details a study commissioned by 3M that investigates the effects of perfluorinated alkyl sulfonates (PFAS) on cholesterol and bile acid metabolism in ApoE3Leiden transgenic mice and rat hepatocytes. 1901 AR226-3763 50DBzMoQnmkg2OeY33yndkKwN 35
The TNO report details a study commissioned by 3M that investigates the effects of perfluorinated alkyl sulfonates, specifically PFBS and PFHS, on cholesterol and bile acid metabolism in transgenic ApoE3Leiden mice and rat hepatocytes, highlighting significant metabolic alterations. 1901 AR226-3758 oez5Z7LZQ1bw82YyLB3Rxv22r 207
The document discusses historical data on C-8 (PFOA) exposure among workers at Washington Works, noting that while C-8 was found in the blood of exposed workers, no significant health issues or disease incidence were linked to the exposure, and it highlights the correlation between blood and air levels of C-8. AR226-3760 v1ZJ6oKB2Oap1DQQ0VEkmVZw9 11